KRYS Share Price Performance
US$251.68
64.53 (34.48%)
13.6% undervalued intrinsic discount
US$291.22
Fair Value
Price US$251.68
AnalystConsensusTarget US$291.22
Vestra US$314.00
AnalystLowTarget US$241.00
Fair ValueUS$291.22
Share Pricen/a
Krystal Biotech, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 61 Fair Values set on narratives written by author
KRYS Community Narratives
AN
Fair Value US$291.22 13.6% undervalued intrinsic discount
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
VE
Fair Value US$314 19.8% undervalued intrinsic discount
Krystal Biotech (KRYS): The "Gene Delivery" Disruptor vs. Launch Complexity
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$241 4.4% overvalued intrinsic discount
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Krystal Biotech (KRYS): The "Gene Delivery" Disruptor vs. Launch Complexity
Krystal Biotech (KRYS) is currently consolidating its recent gains today, March 19, 2026, as the biotech sector navigates broader macroeconomic volatility. The stock closed the session at $258.00 USD , holding flat after a period of intense institutional interest following its Q4 2025 earnings beat.Read more
40
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Aging Populations And AI Will Accelerate Gene Therapy Adoption
Key Takeaways Rapid market penetration and strong operational scalability for VYJUVEK are expected to substantially increase revenue, margins, and earnings power beyond current analyst expectations. Robust pipeline progress, first-mover advantages, and AI-driven patient engagement initiatives could unlock multiple high-margin revenue streams and greater long-term growth.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$371
32.2% undervalued intrinsic discount
Fair Value
Revenue
52.24% p.a.
Profit Margin
68.28%
Future PE
14.57x
Price in 2029
US$451.44
Uncertain Gene Therapy Dynamics Will Fuel Challenges Yet Spark Hope
Key Takeaways Reliance on Vyjuvek faces challenges from unpredictable patient treatment patterns, pricing pressures, and reimbursement risks, impacting both revenue visibility and long-term margin stability. Expanding into new indications through the pipeline and broader patient access drives costs and risk, particularly given high R&D investment and dependence on successful clinical outcomes.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$241
4.4% overvalued intrinsic discount
Fair Value
Revenue
25.89% p.a.
Profit Margin
38.72%
Future PE
29.53x
Price in 2029
US$293.31
KRYS: Global Expansion And Pipeline Shifts Will Shape Near-Term Performance
Key Takeaways International launches and broad pipeline expansion are set to diversify revenue streams and enhance market presence beyond a single product. Manufacturing efficiencies and favorable global healthcare trends are likely to increase profitability and support sustained premium pricing.Read more
253
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
US$291.22
13.6% undervalued intrinsic discount
Fair Value
Revenue
33.38% p.a.
Profit Margin
49.96%
Future PE
23.22x
Price in 2029
US$353.97
Trending Discussion
Recently Updated Narratives
VE
Krystal Biotech (KRYS): The "Gene Delivery" Disruptor vs. Launch Complexity
Fair Value: US$314 19.8% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Future CF And Ophthalmology Readouts Will Shape Long Term Upside
Fair Value: US$371 32.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KRYS: Rising Oncology And Respiratory Pipeline Expectations May Test Rare Disease Optimism
Fair Value: US$241 4.4% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Krystal Biotech, Inc. Key Details
About KRYS
- Founded
- 2016
- Employees
- 295
- CEO
- WebsiteView website
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
